Citius Oncology shares tumble as Q3 revenue misses forecasts despite LYMPHIR launch momentum

Citius Oncology Inc. reported fiscal third-quarter results that disappointed the investment community, with the company’s stock declining 10.05% in pre-market trading. Quarterly revenue reached $1.5 million, substantially trailing the analyst consensus forecast of $12.52 million. The company posted a loss of $0.34 per share against expectations for earnings of $0.03 per share. For the nine-month period ended June 30, 2026, the company generated $7.1 million in total revenue.
Despite the r